美股A股
StockGist
Back
8-K2026-05-04· grok-4-1-fast-non-reasoning

RZLT · Rezolute, Inc.

0001104659-26-054943

SEC filing

Summary

Rezolute announced oral presentation of Phase 3 sunRIZE study results showing ersodetug's clinically relevant glycemic improvements in congenital hyperinsulinism patients despite missing primary endpoint.

Key takeaways

Full analysis

Rezolute presented expanded Phase 3 sunRIZE analyses at the Pediatric Endocrine Society 2026 Annual Meeting, highlighting ersodetug's potential despite the study missing its primary endpoint on SMBG-measured hypoglycemia events. The Company attributes this to functional unblinding and placebo arm effects, with CGM data providing stronger evidence: >50% reductions in time in hypoglycemia (FAS/PPS), 50-80% fewer weekly events, 25-50% increases in normoglycemia exposure, and 10-15 mg/dL average glucose rises, all nominally significant across maintenance dosing. In the ongoing open-label extension, high retention (57/59 participants) demonstrates sustained benefits over 6-24 months, including SOC reductions like diazoxide and somatostatin analogs, with many on ersodetug monotherapy. Rollover placebo patients showed marked improvements versus controlled phase. This data was discussed in a March 17, 2026 FDA Type B meeting, where the agency noted SMBG challenges and requested comprehensive submission to evaluate next steps. Chief Medical Officer Brian Roberts emphasized target engagement and therapeutic potential, positioning ersodetug to address congenital hyperinsulinism across ages 3 months to 45 years in this global 63-patient trial.